Egypt achieves pharmaceutical breakthrough with local insulin production

CAIRO – 30 December 2024: The head of the Egyptian Drug Authority (EDA), Ali El-Ghamrawy, emphasized the Authority's collaboration with local and international partners to fulfill presidential directives on localizing the production of critical medications, particularly for chronic diseases like diabetes.

El-Ghamrawy announced the release of the first batch of locally manufactured Insulin Glargine, highlighting the ongoing efforts to enhance domestic industrial capacity. This initiative aligns with President Abdel Fattah El-Sisi’s vision of improving local manufacturing quality and supporting self-sufficiency in the pharmaceutical sector.

He noted that Egypt is not merely a consumer of technology but an active partner in its development. By adhering to regulations established by the EDA and following global guidelines, Egypt continues to strengthen its position as a significant player in biopharmaceutical manufacturing.

The local insulin manufacturing project aims to produce one of the most vital life-saving medications, pivotal for millions of diabetes patients. Insulin Glargine has been among the best-selling drugs, with a compound annual growth rate of 19% over the past five years (2019-2023). This project not only boosts healthcare quality for Egyptians but also reduces dependence on imports.

This achievement is expected to save $30 million in import costs by the end of September. With a production capacity of 100 million units, the locally produced insulin will meet domestic demand and be exported to 56 countries under partnership agreements. This contributes to the sustainability of Egypt’s pharmaceutical ecosystem and positions the country as a leader in drug manufacturing.

The EDA reaffirmed its commitment to supporting major national projects by providing a regulatory framework that fosters innovation and competitiveness. The Authority continuously updates its standards to ensure Egyptian pharmaceutical products maintain global quality benchmarks, meeting the expectations of the Egyptian people.

The localization of pharmaceutical manufacturing enhances local expertise in biotechnology and pharmaceutical production. It also contributes to scientific research and innovation, allowing local resources to be invested in the development of pharmaceutical formulations.

Insulin Glargine, produced at a capacity of 100 million vials and 50 million cartridges, is the first long-acting insulin of its kind manufactured in Egypt and Africa. Meeting global quality standards, the insulin is widely available for patients, ensuring a steady supply for critical care.

After fulfilling domestic needs, the surplus will be exported to 56 countries, generating foreign currency and reinforcing Egypt's position in the global pharmaceutical industry.